GSK3B and Cognitive impairment: In this study, we used medium doses of GSK3β inhibitors, and previous studies reported that these dosages significantly inhibited GSK3β activity but rarely caused behavioral and cognitive deficits (Mines, 2013; Xing et al., 2016; Nguyen et al., 2017; Pan et al., 2018; Xiang et al., 2021).